Medivir to present at the Redeye Fight Cancer Day
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Fight Cancer Day, today January 24, 2024. CEO Jens Lindberg will present the company and updated data from the ongoing phase 1b/2a clinical study with fostroxacitabine bralpamide (fostrox) at 15.20 CET. The presentation is live broadcasted and can be followed at the event page; https://www.redeye.se/events/966280/redeye-theme-fight-cancer-2